Literature DB >> 23552726

Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.

Siyoung Lee1, Youngmin Lee, Kwangwon Hong, Jaewoo Hong, Suyoung Bae, Jida Choi, Hyunjhung Jhun, Areum Kwak, Eunsom Kim, Seunghyun Jo, Charles A Dinarello, Soohyun Kim.   

Abstract

α1-Antitrypsin (AAT) is a member of the serine proteinase inhibitor family that impedes the enzymatic activity of serine proteinases, including human neutrophil elastase, cathepsin G and neutrophil proteinase 3. Here, we expressed recombinant AAT by fusing the intact AAT gene to the constant region of IgG1 to generate soluble recombinant AAT-Fc protein. The recombinant AAT-Fc protein was produced in Chinese hamster ovary (CHO) cells and purified using mini-protein A affinity chromatography. Recombinant AAT-Fc protein was tested for antiinflammatory function and AAT-Fc sufficiently suppressed tumor necrosis factor (TNF)-α-induced interleukin (IL)-6 in human peripheral blood mononuclear cells (PBMCs) and inhibited cytokine-induced TNFα by different cytokines in mouse macrophage Raw 264.7 cells. However, AAT-Fc failed to suppress lipopolysaccharide-induced cytokine production in both PBMCs and macrophages. In addition, our data showed that AAT-Fc blocks the development of hyperglycemia in a streptozotocin-induced mouse model of diabetes. Interestingly, we also found that plasma-derived AAT specifically inhibited the enzymatic activity of elastase but that AAT-Fc had no inhibitory effect on elastase activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552726      PMCID: PMC3667213          DOI: 10.2119/molmed.2012.00308

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  38 in total

1.  DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z.

Authors:  D W Cox; S L Woo; T Mansfield
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

2.  Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus.

Authors:  D M Heywood; M W Mansfield; P J Grant
Journal:  Diabet Med       Date:  1996-08       Impact factor: 4.359

3.  C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele.

Authors:  M E Griffith; J U Lovegrove; G Gaskin; D B Whitehouse; C D Pusey
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

4.  Serum alpha-1-antitrypsin concentration during normal and diabetic pregnancy.

Authors:  B Lisowska-Myjak; G Sygitowicz; B Wolf; J Pachecka
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-11       Impact factor: 2.435

5.  Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Authors:  Maria Koulmanda; Manoj Bhasin; Lauren Hoffman; Zhigang Fan; Andi Qipo; Hang Shi; Susan Bonner-Weir; Prabhakar Putheti; Nicolas Degauque; Towia A Libermann; Hugh Auchincloss; Jeffrey S Flier; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

6.  [Alpha-1-antitrypsin, albumin and whole protein in meconium and stools during the first days of life in the neonate].

Authors:  B Lisowska-Myjak; J Pachecka; B Antoniewicz; A Krawczyk; A Jóźwik
Journal:  Pediatr Pol       Date:  1995-10

7.  Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.

Authors:  Philippa J Talmud; Steve Martin; George Steiner; David M Flavell; David B Whitehouse; Sylvia Nagl; Richard Jackson; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-06       Impact factor: 8.311

8.  Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice.

Authors:  S Song; K Goudy; M Campbell-Thompson; C Wasserfall; M Scott-Jorgensen; J Wang; Q Tang; J M Crawford; T M Ellis; M A Atkinson; T R Flotte
Journal:  Gene Ther       Date:  2004-01       Impact factor: 5.250

9.  Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT.

Authors:  M A King; J A Stone; P T Diaz; C F Mueller; W J Becker; J E Gadek
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

10.  Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance.

Authors:  M Laakso; M Malkki; P Kekäläinen; J Kuusisto; S S Deeb
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

View more
  13 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

Review 2.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

Review 3.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 4.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

5.  Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.

Authors:  Danny Jonigk; Mariam Al-Omari; Lavinia Maegel; Meike Müller; Nicole Izykowski; Jaewoo Hong; Kwangwon Hong; Soo-Hyun Kim; Martina Dorsch; Ravi Mahadeva; Florian Laenger; Hans Kreipe; Armin Braun; Galit Shahaf; Eli C Lewis; Tobias Welte; Charles A Dinarello; Sabina Janciauskiene
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-23       Impact factor: 11.205

6.  IL-32-induced Inflammatory Cytokines Are Selectively Suppressed by α1-antitrypsin in Mouse Bone Marrow Cells.

Authors:  Siyoung Lee; Dong-Ki Choi; Areum Kwak; Sinae Kim; Tam Thanh Nguyen; Gaae Gil; Eunhye Kim; Kwang Ha Yoo; In Ae Kim; Youngmin Lee; Hyunjhung Jhun; Edward D Chan; Xiyuan Bai; Hyunwoo Kim; Yong-Sung Kim; Soohyun Kim
Journal:  Immune Netw       Date:  2017-04-20       Impact factor: 6.303

7.  Point Mutation of a Non-Elastase-Binding Site in Human α1-Antitrypsin Alters Its Anti-Inflammatory Properties.

Authors:  Yotam Lior; Mariana Zaretsky; David E Ochayon; Diana Lotysh; Boris M Baranovski; Ronen Schuster; Ofer Guttman; Amir Aharoni; Eli C Lewis
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561

8.  S-Nitrosylation of α1-Antitrypsin Triggers Macrophages Toward Inflammatory Phenotype and Enhances Intra-Cellular Bacteria Elimination.

Authors:  Ziv Kaner; Rotem Engelman; Ronen Schuster; Peleg Rider; David Greenberg; Yossef Av-Gay; Moran Benhar; Eli C Lewis
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

9.  Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation.

Authors:  Wenyu Gou; Jingjing Wang; Lili Song; Do-Sung Kim; Wanxing Cui; Charlie Strange; Hongjun Wang
Journal:  Am J Transplant       Date:  2020-11-16       Impact factor: 9.369

10.  Excessive Neutrophil Activity in Gestational Diabetes Mellitus: Could It Contribute to the Development of Preeclampsia?

Authors:  Lenka Vokalova; Shane V van Breda; Xi Lun Ye; Evelyn A Huhn; Nandor G Than; Paul Hasler; Olav Lapaire; Irene Hoesli; Simona W Rossi; Sinuhe Hahn
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.